You are here: Industry Insights > Daiichi Sankyo

News List

EC approves Nilemdo™ (bempedoic acid) for lowering cholesterol europeanpharmaceuticalreview
April 10, 2020
The European Commission has granted Esperion approval for Nilemdo, the company has sold commercialisation rights to Daiichi Sankyo.
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan pharmaceutical-business-review
April 02, 2020
Daiichi Sankyo announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW).
American Regent Expands API Ops contractpharma
April 02, 2020
American Regent, a U.S. manufacturer of pharmaceuticals with manufacturing sites in New York and Ohio, will acquire Daiichi Sankyo Altkirch SARL.
Immunic Licenses IMU-856 from Daiichi Sankyo americanpharmaceuticalreview
January 13, 2020
Immunic announced its subsidiary, Immunic AG, under the terms of its existing option and license agreement with Daiichi Sankyo, has exercised its exclusive global option to license a group of compounds, designated by Immunic as IMU-856.
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial worldpharmanews
December 17, 2019
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of ...
Mitsubishi Tanabe, Daiichi Sankyo tie alliance for ALS treatment agent biospectrumasia
September 18, 2019
Daiichi Sankyo has its own sales and marketing organization in Brazil, and is strengthening its presence in Central and South America as one of initiatives to increase regional value in line with the market characteristics in each region.
Mitsubishi Tanabe, Daiichi Sankyo tie alliance for ALS treatment agent biospectrumasia
September 17, 2019
Through cooperation in Brazil, Mitsubishi Tanabe Pharma and Daiichi Sankyo will aim to provide edaravone to more ALS patients as soon as possible.
Daiichi Sankyo wades deeper into oncology with FDA go-ahead in rare joint cancer fiercepharma
August 13, 2019
In a win for Daiichi Sankyo’s big pivot to oncology, the Japanese drugmaker has snatched its first U.S. cancer nod since 2011—and it’s also the first FDA-approved drug for a rare joint tumor.
Daiichi Sankyo secures FDA approval for Turalio to treat TGCT patients pharmaceutical-technology
August 06, 2019
Daiichi Sankyo has secured the US Food and Drug Administration (FDA) approval for its Turalio (pexidartinib) capsules to treat adult patients with symptomatic tenosynovial giant cell tumour (TGCT).
FDA approves Daiichi Sankyo's TURALIO biospectrumasia
August 05, 2019
TURALIO is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Previous page 1 2 3 4 5 6 7 8 Next page